A5071909609- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Bladder and Urothelial Cancer Treatments
- Breast Cancer Treatment Studies
- Head and Neck Cancer Studies
- Urologic and reproductive health conditions
- Endometrial and Cervical Cancer Treatments
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Advances in Oncology and Radiotherapy
- Cancer, Lipids, and Metabolism
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- Health Systems, Economic Evaluations, Quality of Life
- Estrogen and related hormone effects
- Colorectal Cancer Surgical Treatments
- Hormonal and reproductive studies
- Ovarian cancer diagnosis and treatment
- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Medical Image Segmentation Techniques
- Colorectal and Anal Carcinomas
- Salivary Gland Tumors Diagnosis and Treatment
Université Grenoble Alpes
2014-2024
Boston Medical Center
2024
Centre Hospitalier Universitaire de Grenoble
2014-2023
Centre de Radiothérapie Bayard
1998-2020
Hôpital Albert Michallon
2003-2018
Radboud University Medical Center
2016
Radboud University Nijmegen
2016
Université Joseph Fourier
1994-2013
GTx (United States)
2013
University of Verona
2012
We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head neck cancer.
We conducted a randomized, prospective trial comparing external irradiation with plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces testosterone secretion) in patients locally advanced prostate cancer.From 1987 to 1995, 415 cancer were randomly assigned receive radiotherapy alone or immediate treatment goserelin. The had median age 71 years (range, 51 80). Patients both groups received 50 Gy radiation the pelvis over period five weeks and an additional 20 two...
The combination of radiotherapy plus long-term medical suppression androgens (> or = 2 years) improves overall survival in patients with locally advanced prostate cancer. We compared the use short-term androgen treatment cancer.We randomly assigned cancer who had received external-beam 6 months to two groups, one receive no further (short-term suppression) and other 2.5 years a luteinizing hormone-releasing hormone agonist (long-term suppression). An outcome noninferiority as required hazard...
PURPOSE: To identify prognostic factors for survival in adult patients with cerebral low-grade glioma (LGG), to derive a scoring system, and validate results using an independent data set. PATIENTS AND METHODS: European Organization Research Treatment of Cancer (EORTC) trial 22844 EORTC 22845 are the largest phase III trials ever carried out LGG. The were designed investigate dosage timing postoperative radiotherapy Cox analysis was performed on 322 from (construction set), validated 288...